Cour Pharmaceuticals Development is developing nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients.
Cour Pharmaceuticals Development has raised $50.0M in total funding. The most recent round was Series B. The last funding was announced in June 2026.
Cour Pharmaceuticals Development's investors include Sanofi, Lumira Ventures, Alpha Wave Global, Pfizer Venture Investments, Bristol-Myers Squibb.
Cour Pharmaceuticals Development is headquartered in Skokie, United States.
Cour Pharmaceuticals Development is developing nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients.
Cour Pharmaceuticals Development is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cour Pharmaceuticals Development — Funding & Investors." VCBacked, June 18, 2026, https://www.vcbacked.co/company/cour-pharmaceuticals-development. Accessed September 14, 2026.
VCBacked. (2026). Cour Pharmaceuticals Development — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/cour-pharmaceuticals-development
{{cite web |title=Cour Pharmaceuticals Development — Funding & Investors |url=https://www.vcbacked.co/company/cour-pharmaceuticals-development |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated